Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo

Léon Mbiyangandu Kazumba¹ *, Jean-Claude Tshinzobe Kaka², Dieudonné Mumba Ngoyi³,⁴, Désiré Tshala-Katumbay¹,⁴,⁵

¹ Département de Neurologie, Université de Kinshasa, Kinshasa, République Démocratique du Congo (RDC), ² Institut Supérieur de Techniques Médicales, Kinshasa, Démocratique du Congo (RDC), ³ Département de Médecine Tropicale, Université de Kinshasa, Kinshasa, Démocratique du Congo (RDC), ⁴ Institut National de Recherches Biomédicales (INRB), Kinshasa, Démocratique du Congo (RDC), ⁵ Département of Neurology and School of Public Health, Oregon Health & Science University, Portland, OR, United States of America

* leon_kazumba@yahoo.com

Abstract

We conducted a retrospective study on mortality trends and risk factors in 781 naïve cases of advanced stage-2 sleeping sickness admitted between 1989 and 2012 at the National Reference Center for Human African Trypanosomiasis (HAT), Department of Neurology, Kinshasa University, Democratic Republic of Congo (DRC). Death was the outcome variable whereas age, gender, duration of disease, location of trypanosomes in body fluids, cytorachy, protidorachy, clinical status (assessed on a syndromic and functional basis) on admission, and treatment regimen were predictors in logistic regression models run at the 0.05 significance level. Death proportions were 17.2% in the standard melarsoprol schedule (3-series of intravenous melarsoprol on 3 successive days at 3.6 mg/kg/d, with a one-week interval between the series, ARS 9); 12.1% in the short schedule melarsoprol (10 consecutive days of intravenous melarsoprol at 2.2 mg/kg/d, ARS 10), 5.4% in the first-line eflornithine (14 days of eflornithine at 400 mg/kg/d in 4 infusions a day DFMO B), 9.1% in the NECT treatment regimen (eflornithine for 7 days at 400, mg/kg/d in 2 infusions a day combined with oral nifurtimox for 10 days at 15 mg/kg/d in 3 doses a day); and high (36%) in the group with select severely affected patients given eflornithine because of their clinical status on admission, at the time when this expensive drug was kept for treatment of relapses (14 days at 400 mg/kg/d in 4 infusions a day, DFMO A). After adjusting for treatment, death odds ratios were as follows: 10.40 [(95% CI: 6.55–16.51); p = .000] for clinical dysfunction (severely impaired clinical status) on admission, 2.14 [(95% CI: 1.35–3.39); p = .001] for high protidorachy, 1.99 [(95% CI: 1.18–3.37); p = .010] for the presence of parasites in the CSF and 1.70 [(95% CI: 1.03–2.81); p = .038] for high cytorachy. A multivariable analysis within treatment groups retained clinical status on admission (in ARS 9, ARS 10 and DFMO B groups) and high protidorachy (in ARS 10 and DFMO B groups) as significant predictors of death. The algorithm for initial clinical status assessment used in the present study may
serve as the basis for further development of standardized assessment tools relevant to the clinical management of HAT and information exchange in epidemiological reports.

Author summary

This study reports on the importance of recording data related to the clinical presentation on admission in sleeping sickness. We collected data on 781 second-stage patients admitted in the Trypanosomiasis Unit of the Department of Neurology of the University of Kinshasa from 1989 to 2012. The following information were registered: age, sex, symptomatology duration, trypanosome parasites location in body fluids, clinical presentation on admission, cerebrospinal fluid (CSF) cell count, CSF protein concentration, therapeutic regimen, and post-treatment outcome in terms of death or survival. Analyses demonstrated that the most influential factor on the occurrence of death was a dysfunctional clinical status on admission (reflecting advanced disease). These results support the idea that the algorithm used to categorize patients in the present work can be proposed for validation in prospective studies with the purpose of designing a standardized clinical procedure assessing disease severity and bearing predictive value of outcome.

Introduction

The clinical management of HAT has always been confronted with the issue of treatment efficacy, drug toxicity and mortality risk factors [1–6]. In the process of assigning the probable cause of death to disease progression, treatment side effects, or any other factors including but not limited to coexistent pathology, the assessment of clinical status on admission among the baseline characteristics may be crucial [2,7]. The clinical presentation of HAT has been abundantly described in previous literature [8–12]. After a period of general manifestations (Stage 1), the gambiense form of HAT is characterized by a protracted course with a vast spectrum of symptoms and signs reflecting progressive involvement of multiple sites of central and peripheral nervous system (CNS, PNS) (Stage 2) that can last several years. The heterogeneous symptomatology that ensues can be summarized in three main categories: alertness and mental disturbances, motor and sensory symptoms, and sleep disturbances that owed the disease its name. If untreated the patient enters a terminal stage with incoherence, repeated seizures, double incontinence, eventually cachexia, coma and death, as a result of major brain demyelination and atrophy [13].

The pertinence of including clinical aspects in the current case definition has been perceived by experts who called for standardization of HAT clinical records [7,14–17] However some authors have raised concerns about the interpretation of clinical data collected by examiners with different level of training [2,11,12] and only few studies have addressed the issue of the prognostic value of clinical presentation in treated HAT [9,10,18,19]. With the advent of new diagnostic tools and safe, easy-to-take medicines, the WHO has planned to maintain the present decreasing endemicity trend and considers elimination of HAT in the coming years a realistic target [20–22]. Some long-standing practices such as the current mandatory requirement of accurate stage determination for drug allocation are likely to be revised soon [20–22]. One of the strategic changes in the fight against HAT is a special emphasis on passive case detection further involving fixed health care settings and launching new insights on the clinical aspects of the disease. It is therefore of paramount relevance that HAT health-care workers...
and scientists are provided with a standardized clinical evaluation tool. Such assessment tool would facilitate comparison of results in large scale multicenter studies.

The present paper draws on a 23-year-experience of care to sleeping sickness patients in a specialized center and intends to assess the impact of pre-treatment clinical status as well as select biological factors on mortality rate.

**Methods**

We retrospectively examined hospital records of naïve cases of stage-II HAT admitted and treated in the Unit of HAT of the Department of Neurology at the University of Kinshasa from 1989 to 2012. The aforementioned unit was officially designated in March 2001 to serve as the National Reference Centre for HAT in collaboration with the Congo National Program against HAT. Sleeping sickness diagnosis is completed at the CNRTHA or through the referral system of the National Program (Mobile teams or select first-level medical centers). Ethical approval was obtained from the institutional Review Board of the INRB (Institut National de Recherches Biomédicales) and all data analyzed in our study were anonymized to protect confidentiality.

**Inclusion and exclusion criteria**

Subjects with confirmed parasitological diagnosis of HAT (trypanosomes detected by direct microscopic examination of blood, lymph juice or cerebrospinal fluid), stage-2 disease, and complete medical records were included in the present study. Subjects were considered in stage-2 HAT when trypanosomes were found in the CSF and, or the white blood cell (WBC) count in the cerebrospinal fluid (CSF) was more than 5 cells/m$^3$ and/or the total protein concentration $> 45$ mg/dl (Biuret method) \cite{23,24}. This latter exam is routinely practiced at the CNRTHA, but is not part of the current investigations in first-level settings. Cases in stage-1 disease or admitted for sequelae or relapse were not included in the study (S1 Diagram Flow).

**Variables of interest**

Death was considered as the dependent variable. Independent variables (predictors) included age, sex, duration of the disease, location of the parasites in body fluids at the time of the diagnosis, CSF WBC, CSF total protein concentration, clinical status on admission, and treatment regimen.

The clinical status on admission was categorized following a bi-axial clinical assessment inventory set up on the ground of our experience in the management of sleeping sickness patients. This assessment procedure is similar to that reported in a previous study \cite{19}. In the new version we added to the assessment based on the record of clinical signs (syndromic axis) an evaluation of the functioning based on the level of impairment of three basic functions: speaking, walking and swallowing (functional axis). For each patient the following data were extracted from the medical file. In one hand the presence or absence of nine clinical items: behavioral changes or altered awareness (any modification of any aspect of behavior), archaic reflexes (palmo-mental reflex or grasping reflex), rigidity (cog-wheel or lead-pipe hypertonia), cerebellar dysfunction (intention tremor or dysmetria or dysdiadochokinesia or wide-based gait), dyskinesia (chorea or athetosis or dystonia), hemiparesis, incontinence, neck stiffness, and weight loss; in the other hand the level of impairment in speaking, walking and swallowing quoted as intact, partially impaired or lost. The assessment procedure is shown in the chart below (Table 1).

Patients were treated according to the guidelines of the WHO and the National HAT Program. The following regimens were used over time: 3 series of intravenous (i.v) melarsoprol on 3 successive days at 3.6 mg/kg/d, with a one-week free interval between the series (long schedule melarsoprol regimen, herein referred to as ARS 9) from 1989 to 2000; 10 consecutive days i.v. melarsoprol at 2.2 mg/kg/d (short schedule melarsoprol regimen, herein referred to as
ARS 10) from 2000 to 2006; 14 days of eflornithine at 400 mg/kg/d in 4 infusions a day (first-line eflornithine regimen, herein referred to as DFMO B) from 2007 to 2009; a combination of eflornithine for 7 days at 400 mg/kg/d in 2 infusions a day with oral nifurtimox for 10 days at 15 mg/kg/d in 3 doses a day (herein referred to as NECT regimen) from 2010 to 2012. Eflornithine was also given at the same dosage as DFMO B to select severely affected patients to avoid exposing them to the risk of melasoprol severe adverse events (selective eflornithine, herein referred to as DFMO A regimen) between 1989 and 2006. Patients with deglutition difficulties were fed or given drugs via a nasogastric tube.

Statistical analysis

Data on age, duration of disease, WBC, and total protein concentration in the CSF were dichotomized using arbitrary cut-off points of 15 years, 6 months, 100 WBC/ml, and 100 mg protein/dl, respectively. Clinical status on admission was dichotomized into "dysfunctional status" and "non-dysfunctional status" and parasitological diagnosis was analyzed considering the presence of trypanosomes whether in CSF or not. Treatment regimens were compared in reference to DFMO B regimen. Logistic regression models were used to assess the association between death and the aforementioned independent variables including gender. Statistical analyses were conducted using Stata software (version 11.2, Stata Corp Inc.) at the significance level of 0.05.

Results

Yearly admission rates of the 781 Stage-2 HAT patients

Admissions rates remarkably changed over the study period and were the highest in 2001 and 2007, mainly due to the discovery of new endemic foci of HAT in the villages of Kimwenza and Muwana, respectively. The decrease in the rate of admissions from 2009 and onwards followed the drawback of the HAT endemicity in the country (Fig 1).

General and clinical characteristics in the 781 study subjects

The frequencies of clinical features from the syndromic and functional assessments are reported in Tables 2 and 3 while the data on the variables of interest are displayed in Table 4.

Death rates and risk factors

Of the 781 patients included in the present analysis, death was recorded in 102 (13.1%) cases. The annual distribution of fatality rates varied over the study period and overlapped with the

---

Table 1. Stage-2 HAT severity assessment chart.

| Number of signs present (out of 9) | Level of impairment of 3 functions | Severity grade | Dichotomized category |
|-----------------------------------|-----------------------------------|----------------|----------------------|
| Absent (Asymptomatic)             | All functions preserved           | Grade 0        | Non-Dysfunctional     |
| 1 to 2 signs (Paucisymptomatic)   | Partial impairment of 1 or 2 functions | Grade 1        | Non-Dysfunctional     |
| 3 or more signs (Multisymptomatic)| Partial impairment of 1 or 2 functions | Grade 2        | Non-Dysfunctional     |
| Any number of signs               | Partial impairment of 3 or complete loss of 1 or 2 functions = "hypofunctional status") | Grade 3        | Dysfunctional         |
| Any number of signs               | All functions lost ("afunctional status" = akinetic mutism) | Grade 4        | Dysfunctional         |

Disease severity is assessed as “Non-Dysfunctional” (Grades 0, 1 or 2) or “Dysfunctional” (Grades 3 or 4).
distribution of the dysfunctional cases and no peak of deaths was observed in 2007 (year of introduction of DFMO B) as compared to 2001. These characteristics suggest an influence of

Table 2. Syndromic and functional aspects of clinical presentation in the 781 study subjects.

| Syndromic Assessment               | N  | %  |
|------------------------------------|----|----|
| Behavioral changes or Altered awareness | 536 | 68.6 |
| Archaic reflexes                   | 466 | 60.1 |
| Rigidity                           | 428 | 54.8 |
| Weight loss                        | 428 | 54.8 |
| Neck stiffness                      | 380 | 48.7 |
| Cerebellar signs                   | 356 | 45.6 |
| Incontinence                       | 212 | 27.1 |
| Hemiparesis                        | 172 | 22.0 |
| Dyskinesia                         | 114 | 14.6 |

| Functional Assessment              | N  | %  |
|------------------------------------|----|----|
| Walking Impairment                 | 207 | 26.5 |
| Speech Impairment                  | 186 | 23.8 |
| Deglutition Impairment             | 91  | 11.6 |

https://doi.org/10.1371/journal.pntd.0006504.t002
both, clinical presentation and treatment regimen on case fatality rate (Fig 2). Besides, the number of deaths increased consistently with disease severity on admission. Those admitted in non-dysfunctional state (Grade 0, 1 or 2) were interpreted as “unexpected deaths” (Fig 3).

Death rates per treatment group were as follows: 17.2% in the ARS 9 group, 12.1% in the ARS 10 group, 5.4% in the DFMO B group, 9.1% in the NECT group and exceptionally high (36%) in the DFMO A group. The difference in death rates across the five groups was statistically significant (Likelihood-ratio Chi2 (4) = 27.41; \( p < 0.001 \)). The difference in death rates between the two melarsoprol groups was not significant (Pearson Chi2 (1) = 2.8; \( p = 0.08 \)).

However, of the 42 deceased while clinically non-dysfunctional (not severely affected on admission), 37 (88.1%) were treated with melarsoprol. The highest proportion of non-dysfunctional cases among the deceased (“unexpected deaths”) was registered with ARS 10 (67.6%) in contrast to DFMO A (7.7%), which was administered exceptionally to a severely affected

| Severity grade                        | N   | %  |
|---------------------------------------|-----|----|
| Grade 0                               | 84  | 10.8 |
| Grade 1                               | 416 | 53.3 |
| Grade 2                               | 137 | 17.5 |
| Sub-Total (Non-Dysfunctional)          | 637 | 81.6 |
| Grade 3                               | 101 | 12.9 |
| Grade 4                               | 43  | 5.5  |
| Sub-Total (Dysfunctional)              | 144 | 18.4 |
| Total                                 | 781 | 100 |

https://doi.org/10.1371/journal.pntd.0006504.t003

Table 3. Frequency by severity grade in the 781 study subjects.

| Characteristics                                | ARS 9, N = 226 | ARS 10, N = 307 | DFMO A, N = 36 | DFMO B, N = 168 | NECT, N = 44 | OVERALL, N = 781 |
|------------------------------------------------|----------------|----------------|----------------|-----------------|--------------|------------------|
| Sex                                            | Males          | 133            | 152            | 14              | 88           | 26               | 413             |
|                                                | Females        | 93             | 155            | 22              | 80           | 18               | 368             |
|                                                | Ratio M/F       | 1.4            | 1              | 0.6             | 1.1          | 1.4              | 1.1             |
| Age (years)                                    | Mean±SD        | 30.7 ± 15.0    | 30.8 ± 16.5    | 23.1 ± 20.8     | 29.3 ± 17.3  | 29.5 ± 11.0      | 30.0 ± 16.3     |
|                                                | % (<15 y)      | 14.2           | 16.9           | 16.9            | 16.9         | 16.9             | 16.9            |
| Duration (months) a                            | Mean±SD        | 11.4 ± 13.6    | 9.0 ± 11.9     | 8.4 ± 5.4       | 11.1 ± 15.2  | 5.7 ± 9          | 9.9 ± 12.8      |
|                                                | % (>6 m)       | 66.7           | 21.2           | 57.6            | 50.6         | 36.4             | 51.8            |
| Clinical presentation on admission             | % (Dysfunctional) | 17.3          | 13.4           | 66.7            | 13.7        | 18.2             | 18.4            |
| Parasites location                             | % (CSF+) b     | 75.1           | 66.8           | 83.3            | 59.5        | 90.9             | 69.9            |
| CSF WBC (count/ml) c                          | Mean±SD        | 256.2 ± 303    | 397.9 ± 456    | 463.4 ± 489.3   | 347.0 ± 478.6| 473.7 ± 382.6   | 353.3 ± 425.4   |
|                                                | % (>100)       | 67.9           | 70.0           | 86.1            | 66.1        | 90.7             | 70.4            |
| CSF Proteins (mg/dl)                           | Mean±SD (N)    | 116.6 ± 56.3   | 89.4 ± 53.6    | 108.5 ± 56.4    | 85.6 ± 24.8 (75)| 88.4 ± 13.7 (22) | 99.8 ± 45.7 (559) |
|                                                | % (>100)       | 57.9           | 29.0           | 35.7            | 17.3        | 11.4             | 37.7            |
| CSF WBC ≤ 5 d                                  | N              | 15             | 4              | 1               | 1           | 1               | 21              |

SD = standard deviation; CSF = cerebrospinal fluid; WBC = white blood cells.

a Data were lacking in 22 subjects

b Percentage of cases with trypanosomes present in their CSF

c Data were lacking in 3 subjects

d Subjects classified as stage 2 on the basis of high CSF proteins (> 100 mg/dl).

https://doi.org/10.1371/journal.pntd.0006504.t004
group (Fig 4). Differences in proportions of unexpected deaths were significant when comparing ARS 9 and ARS 10 (Pearson Chi2 (1) = 10.29; \( p = 0.001 \)) or ARS 10 and DFMO B (Fisher exact test; \( p = 0.018 \)).

Overall univariable regression analysis indicates that death was significantly associated with the clinical status on admission, presence of parasites in the CSF, treatment regimen, total protein concentration, and WBC in the CSF (Table 5).

Association models by treatment group showed that only dysfunction in 4 groups (ARS 9, ARS 10, DFMO A and DFMO B) and high total CSF protein concentration in 2 groups (ARS 10 and DFMO B) were significantly associated with death (Table 6).

After adjusting for treatment, the following odds ratios were extracted: 10.40 [(95% CI: 6.55–16.51); \( p = .000 \)] for clinical dysfunction (severely impaired initial clinical status), 2.14 [(95% CI: 1.35–3.39); \( p = .001 \)] for high protidorachy, 1.99 [(95% CI: 1.18–3.37); \( p = .010 \)] for the presence of parasites in the CSF and 1.70 [(95% CI: 1.03–2.81); \( p = .038 \)] for high cytorachy; all in relation to death as the main outcome. A multivariable analysis within treatment groups retained clinical status on admission (in ARS 9, ARS 10 and DFMO B groups) and high protidorachy (in ARS 10 and DFMO B groups) as significant predictors of death (Table 7).

**Discussion**

This study explicitly discusses the role of clinical presentation on admission among current risk factors of death in a large series of second-stage HAT patients. Data from a 23 year-period of clinical management of HAT indicates that clinical presentation on admission, therapeutic regimen and protidorachy were main predictors of death, while high cytorachy was the weakest.

One remarkable finding is the decrease in death rates at the advent of eflornithine as first-line
treatment, a finding consistent with previous studies [5, 25]. In general our study shows higher death rates than reported in HAT literature, as illustrated in the following studies. 17.2% versus 2.7–5% with the standard melarsoprol schedule (ARS9), [3, 25, 26], 12.1% versus 2.4–6.5% with the short melarsoprol schedule (ARS10), [5, 25–27], 5.3% versus 0.4–3.1% with eflornithine (DFMOB) [5, 25, 28, 29] and 9.1% versus 0.7–0.15% with NECT [30, 31]. The relatively higher
rates in our series may be attributed to the so-called center effect for the admitting center is a tertiary-level unit devoted to neuropsychiatric care and serving as a reference center for the national program against HAT and, before 2001, most of the patients were admitted on the basis of neuropsychiatric manifestations. Patients admitted in such a setting are more likely to be diagnosed with advanced sleeping sickness [11,12]. The abnormally higher death rates in the group treated with eflonithine because of advanced disease (DFMOA: case fatality rate = 36%) is expected, as the best drug would not prevent the moribund from dying. The higher rate of death in the NECT group (9.1%) compared to first-line eflornithine (DFMO B) group (5.3%) in our series requires careful interpretation as NECT group had the highest rate of “dysfunctional” cases upon admission (18.2% versus 13.7%), and also higher frequency of cases with other indicators of disease severity (90.7% of cases with high CSF WBC count, 90.9% of cases with parasites in the CSF), compared to DFMOB group 66.1% and 59.5%, respectively) and the sample size was relatively small compared to other groups. In general recent studies show that NECT tends to perform even better than DFMO, at least it proved to be non-inferior in efficiency and of easier management [22] The low in-hospital case fatality rate registered with NECT by Alirol and al (0.15% or 1 of 684 second-stage HAT patients) has to be interpreted taking into account

\[ P \text{Crude OR (95% CI) } P \]

| PREDICTORS          | Crude OR (95% CI) | P  |
|---------------------|-------------------|----|
| Males               | 1.19 (.79–1.81)   | .403 |
| Age <15 years       | 1.0460–1.80)      | .881 |
| Duration ≥6 months  | 1.3990–2.14)      | .140 |
| Parasites in CSF    | 2.04 (1.21–3.44)  | .008 |
| Dysfunctional State | 10.12 (6.41–15.96)| .000 |
| CSF WBC             | 1.00 (1.00–1.00)  | .468 |
| CSF WBC ≥100 cells/ml | 1.70 (1.02–2.83) | .040 |
| CSF Proteins        | 1.01 (1.00–1.01)  | .000 |
| CSF Proteins ≥100 mg/dl | 2.03 (1.28–3.23) | .003 |
| Treatment           | 1.27 (1.08–1.50)  | .004 |

Table 5. Unadjusted odds of death.

Table 6. Unadjusted odds of deaths by treatment group.

| Predictor            | ARS 9, N = 226 | ARS 10, N = 307 | DFMO A, N = 36 | DFMO B, N = 168 | NECT, N = 44 |
|----------------------|---------------|-----------------|----------------|------------------|--------------|
|                      | Crude OR (95% CI) | P  | Crude OR (95% CI) | P  | Crude OR (95% CI) | P  | Crude OR (95% CI) | P  | Crude OR (95% CI) | P  |
| Males                | .77 (.37–1.57)  | .46 | 1.96 (.96–4.01) | .07 | 0.37 (0.09–1.53) | .17 | 4.12 (0.83–20.47) | .08 | 0.45 (0.04–4.72) | .51 |
| Age <15 years        | .70 (.28–1.77)  | .46 | 1.35 (.50–3.64) | .56 | 1.74 (0.44–6.97) | .43 | 2.51 (.30–20.73) | .39 | *             |
| Duration ≥6 months   | 1.42 (0.70–2.88) | .33 | 1.39 (.68–2.84) | .37 | 0.69 (0.16–2.97) | .62 | 1.37 (0.27–7.00) | .71 | 1.00 (0.09–10.74) | 1.00 |
| Parasites present in CSF | 1.58 (.65–3.81) | .31 | 1.94 (.85–4.40) | .12 | 0.50 (0.08–2.94) | .44 | 5.83 (.71–47.70) | .10 | *             |
| Dysfunctional State  | 17.79 (7.85–40.2) | .00 | 3.99 (1.81–8.78) | .00 | 11.00 (1.22–99.07) | .03 | 31.28 (6–163.57) | .00 | 5.67 (.66–48.33) | .11 |
| CSF WBC ≥100 cells/ml | 1.25 (.58–2.68) | .56 | 1.38 (.62–3.06) | .43 | *             |   | 4.35 (.53–35.67) | .17 | *             |
| CSF Proteins ≥100 mg/dl | 1.23 (.59–2.56) | .57 | 2.24 (1.01–4.99) | .05 | 2.60 (0.52–13.04) | .25 | 8.74 (1.67–45.65) | .01 | *             |

*Not applicable due to limitations in sample size.

https://doi.org/10.1371/journal.pntd.0006504.t005

https://doi.org/10.1371/journal.pntd.0006504.t006
the low proportion (2.6%) of cases with high CSF cell count and a better general condition upon admission mostly in children.

Deaths occurring despite a relatively good clinical condition on admission were noted in 42 cases. One striking finding is that most of those unexpected deaths occurred with melarsoprol regimens. In 30 (80%) of the 37 treated with this drug, the severe adverse event that led to death was clearly an encephalopathic reaction; in 2 cases a non-encephalopathic reaction was observed with a preeminence of peripheral nervous system involvement that culminated with acute respiratory distress; in 1 case who died suddenly a cardiogenic etiology was suspected; in the 4 other cases the clinical picture was complex and difficult to interpret. At least in 86.5% of the cases (32/37) the severe adverse event could be related to the drug. Unexpected fatal outcomes raise the issue of the actual cause of death in treated HAT with the intricate question of drug toxicity [1–4,7,32], an open area for further research where, up to now, there are more questions than answers. Diverse situations can occur and a predictive algorithm like the one used in our study is essential in the process of assigning the probable cause of death to disease progression or to other causes such as drug toxicity or concurrent disease [2,7].

Among the biological factors CSF total proteins concentration prevailed in our study, a finding in line with the present day growing interest in proteomics to explore neuropathogenesis of HAT and improve disease staging [17,33–39]. In fact, most articles dealing with disease severity are focused on biological stage determination as a basis for appropriate drug allocation [33,34,39,40]. The importance of clinical manifestations in the process of disease severity assessment is highlighted by the findings in a recent experimental animal study demonstrating that clinical events precede biological changes attesting neuroinvasion by trypanosomes [17]. Furthermore the authors point out to the need for an objective test to assess HAT clinical severity. The issue of stage determination is about to be settled with the advent of safe therapeutics efficient in both stages of HAT as stated above (“stage-independent oral drugs”) [20,22].

Several authors analyzed risk factors of death in treated HAT and some of them included clinical tests borrowed from pathological fields alien to HAT to assess disease severity such as Glasgow coma scale, Karnofski index. However the context of those studies was safety and effectiveness of therapeutic regimens and they did not explicitly discuss the role of clinical presentation among other risk factors of death [4,26,29,31] or they did not find a significant influence of clinical status on the outcome [4]. Literature tackling the issue of the influence of clinical presentation on the outcome of treated HAT is scarce. Two previous studies using a clinical index for disease severity to predict fatal outcome led to contradictory results [18]. In 1993 we published a paper showing a link between the number of neurological signs and fatal outcome in 2 groups of stage-2 HAT patients (19 children and 60 adults) treated with melarsoprol [19] The present study added a functional aspect to the clinical assessment procedure. This has allowed the correct assessment of the most affected subjects in whom elicitation of

### Table 7. Adjusted odds of deaths by treatment group.

| Treatment | Predictors | N = 226 | N = 307 | N = 36 | N = 168 | N = 44 |
|-----------|------------|---------|---------|--------|---------|--------|
| ARS 9     | Males      | 1.04 (0.44–2.46) | 0.92 | 2.16 (1.01–4.63) | 0.05 | .74 (0.13–4.23) | 0.73 | 6.24 (0.77–50.80) | 0.09 | .14 (0.004–4.73) | 0.28 |
|           | Parasites present in CSF | .87 (0.26–2.91) | 0.82 | 1.29 (0.42–3.91) | 0.66 | .67 (0.05–9.61) | 0.77 | 1.13 (0.08–16.44) | 0.93 | * | * |
|           | Dysfunctional State | 19.26 (8.09–45.82) | 0.00 | 3.31 (1.43–7.70) | 0.00 | 27.74 (1.50–345.07) | 0.24 | 16.09 (2.45–105.51) | 0.00 | 15.24 (8.5–271.59) | 0.06 |
|           | CSF WBC≥100 cells/ml | 1.32 (0.49–3.55) | 0.58 | .95 (0.33–2.76) | 0.93 | * | * | 1.61 (1.13–20.61) | 0.71 | .12 (0.00–3.18) | 0.20 |
|           | CSF Proteins ≥100 mg/dl | .76 (0.31–1.87) | 0.55 | 2.26 (1.01–5.07) | 0.05 | 4.93 (0.46–52.17) | 0.18 | 9.33 (1.08–80.80) | 0.04 | * | * |

https://doi.org/10.1371/journal.pntd.0006504.t007
select neurological signs was compromised by lack of collaboration, in contrast to our former study where such patients were underrated. The merit of the present study is certainly the demonstration of the preeminence of the initial clinical status among factors influencing the outcome of treated stage-2 HAT. By properly categorizing 781 stage-2 HAT subjects, we demonstrated that patients admitted in severe clinical condition (“dysfunctional state”) were ~10 times more at risk of dying than those in relatively good clinical condition (“non-dysfunctional state”) on admission, irrespective of the treatment. Our protocol for the initial clinical assessment of subjects represents the first step towards the development of standardized and validated tools for a comprehensive case definition in sleeping sickness. Such tools would prove to be relevant in the clinical tailor-made management of HAT (e.g. to refer on an objective basis toward appropriately equipped settings for the care of the most affected patients), information exchange in epidemiological reports for disease surveillance and control, multicenter clinical trials and literature reviews. They would also provide objective grounds to circumstantiate imputability in pharmacovigilance.

Supporting information
S1 Diagram Flow. Admissions and selection of study subjects. St1, St2 = number of patients admitted in the first stage or second stage of HAT, respectively. Incomplete records = Stage-II HAT cases with incomplete clinical data. (TIFF)

S1 Checklist. STROBE Checklist. (DOCX)

Acknowledgments
We are grateful to the staff of the neurology center and the national program against HAT for providing support and treatment to HAT patients. The Scientific Writing Workshop organized by IBRO and led by Marina Bentivoglio provided opportunity for improving the quality of the manuscript.

Author Contributions
Conceptualization: Léon Mbiyangandu Kazumba, Jean-Claude Tshinzobe Kaka, Désiré Tshala-Katumbay.

Data curation: Léon Mbiyangandu Kazumba.

Formal analysis: Léon Mbiyangandu Kazumba, Jean-Claude Tshinzobe Kaka, Dieudonné Mumba Ngoyi, Désiré Tshala-Katumbay.

Funding acquisition: Désiré Tshala-Katumbay.

Investigation: Léon Mbiyangandu Kazumba.

Methodology: Léon Mbiyangandu Kazumba, Dieudonné Mumba Ngoyi.

Writing – original draft: Léon Mbiyangandu Kazumba, Jean-Claude Tshinzobe Kaka, Dieudonné Mumba Ngoyi, Désiré Tshala-Katumbay.

References
1. Dumas M, Breton JC, Pestre Alexandre M, Girard PL, Giordano C. Current status of the therapy of human African trypanosomiasis. Press Medicale, La. 1985; 14(5):253–6.
2. Nieuwenhove S Van. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop [Internet]. 1992; 72 Suppl 1:39–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1417168%5Cnhttp://lib.itg.be/open/asbmt/1992/1992asbmtos39.pdf

3. Pépin J, Milord F, Khonde AN, Nyonsenga T, Loko L, Mpià B, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1995; 89:89–7. PMID: 7747321

4. Blum J, Nkunu S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop med Int Heal. 2001; 6(5):390–400.

5. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis. Clin Infect Dis [Internet]. 2005; 41(5):748–51. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/432576 https://doi.org/10.1086/432576 PMID: 16080099

6. WHO Expert Committee. Control and surveillance of human African Trypanosomiasis [Internet]. Vol. 984, World Health Organization technical report series. Geneva; 2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24552089

7. Atouguia J, Costa J. Therapy of Human African Trypanosomiasis: Current Situation. Mem Inst Oswaldo Cruz. 1999; 94(2):221–4. PMID: 10224352

8. Gallais P, Badier M. Recherches sur l’encephalite de la trypanosomiase humaine africaine: corrélations cliniques, anatomatopticques, électro-encéphalographiques, biologiques. Méd Trop. 1952; 12(6):633–75.

9. Bertrand E, Serie F, Kone I, Rive J, Compaore Al. Symptomatologie générale de la trypanosomiase humaine au moment du dépistage. Médecine d’Afrique Noire. 1973; 20:303–14.

10. Antoine P. Neurological and psychological studies of patients with sleeping sickness and their course. Ann Soc Belg Med Trop. 1977; 57((4–5)):227–48. PMID: 610608

11. Ginoux PY, Frezil JL, Alary JC. Symptomes de trypanosomiase au cours de la phase diagnostic dans le Republic of Congo. La Trypansos Hum au moment du Depist en Repub Pop du Congo Distrb des signes Clin [Internet]. 1982; 42:281–7. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med2&NEWS=N&AN=7050611

12. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 2006; 97(1):55–64. https://doi.org/10.1016/j.actatropica.2005.08.001 PMID: 16157286

13. Dumas M, Bisser S. Clinical aspects of human African trypanosomiasis. In: Dumas M, Bouteille B, Buguet A, editors. Progress in human African trypanosomiasis, sleeping sickness. Paris: Springer; 1999. p. 215–33.

14. Who. Epidemiology and control of African trypanosomiasis: report of a WHO Expert Committee [Internet]. Geneva; 1986. Available from: http://scholar.google.com/scholar?q=WHO+Epidemiology+and+control+of+African+trypanosomiasis&hl=en&as_sdt=0,5

15. Tiberti N, Hainard A, Lejon V, Courtioux B, Matovu E, Enyaru JC, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One. 2012; 7(7).

16. Buguet A, Bentivoglio M. Human African trypanosomiasis: a highly neglected neurological disease. In: Neglected tropical diseases and conditions of the nervous system. New York: Springer; 2014. p. 165–81.

17. Laperchia C, Palomba M, Etet PFS, Rodgers J, Bradley B, Montague P, et al. Trypanosoma brucei Invasion and T-Cell Infiltration of the Brain Parenchyma in Experimental Sleeping Sickness: Timing and Correlation with Functional Changes. PLoS Neg Trop Dis. 2016; 10(2).

18. Edan G. Clinical and biological symptoms of T. gambiense trypanosomiasis in the meningo-encephalitic period. Med Trop (Mars) [Internet]. 1979; 39(5):499–507. Available from: http://www.ncbi.nlm.nih.gov/pubmed/530039

19. Kazumba M, Kazadi K, Mulumba MP. Caractéristiques de la trypanosomiase de l’enfant. A propos de 19 observations effectuées au CNPP, Cliniques Universitaires de Kinshasa. Ann Soc Belge Méd Trop. 1993; 73:1993.

20. Böscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet. 2017; 6736 (17):1–13.

21. World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense) [Internet]. World Health Organization, WHO press. Geneva; 2012. Available from: www.who.int/about/licensing/copyright_form/en/index.html

22. Eperon G, Balasesgaram M, Potet J, Mowbray C, Valverde O, Chappuis F. Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther [Internet]. 2014;
23. Campbell WR, Hanna MI. The clinical estimation of protein in the cerebrospinal fluid. CanMAJ. 1944; 51:347–50.

24. Finley PR, Williams RJ. Assay of cerebrospinal fluid protein: A rate biuret method evaluated. Clin Chem. 1983; 29(1):126–9. PMID: 6848247

25. Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ. 2006; 84(10):783–91. PMID: 17128358

26. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. 2000; 355(9213):1419–25.

27. Schmid C, Richer M, Bilenge CMM, Josenando T, Chappuis F, Manthelot CR, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis. 2005; 191(March 2004):1922–31.

28. Pépin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: A multicentre randomized controlled trial. Bull World Health Organ. 2000; 78(11):1284–95. PMID: 11143188

29. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ [Internet]. 2008; 336(7646):705–8. Available from: http://www.bmj.com/content/336/7646/705.long%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE(reference&D=med5&NEWS=N&AN=18321960 https://doi.org/10.1136/bmj.39485.592674.BE PMID: 18321960

30. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374(9683):56–64. https://doi.org/10.1016/S0140-6736(09)61117-X PMID: 19559476

31. Alirol E, Schrumpf D, Amici Heradi J, Riedel A, De Patoul C, Quere M, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense: a multicentre experience in the Democratic Republic of the Congo. Clin Infect Dis. 2013; 56(2):195–203. https://doi.org/10.1093/cid/cis886 PMID: 23074318

32. Robays J, Raguenau ME, Josenando T, Boelaert M. Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. 2008; 13(2):265–71.

33. Lejon V, Legros D, Rosengren L, Etchegorry M, Büscher P. Contribution of biochemical tests in the diagnosis of the nervous phase of human African trypanosomiasis. Am J Trop Med Hyg. 1997; 90(5):321–6.

34. Lejon V, Legros D, Rosengren L, Etchegorry M, Büscher P. Detection of light subunit neurofilament and glial fibrillary acidic protein in cerebrospinal fluid of Trypanosoma brucei gambiense—infected patients. Am J Trop Med Hyg. 1999; 60(1):94–8. PMID: 9988330

35. Girard M, Bisser S, Buscher P, Bouteille B, Homme JP. Cross-reactivity of anti-galactocerebroside autoantibodies with a Trypanosoma brucei proteolipidic epitope. Clin Exp Immunol. 2000; 119:516–22. https://doi.org/10.1046/j.1365-2249.2000.01166.x PMID: 10691925

36. J S. Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol. 2004; 26(11–12):469–76. https://doi.org/10.1111/j.0141-9838.2004.00731.x PMID: 15771682

37. Courtieux B, Pervieux L, Bisser S, Bouteille B. [Criteria for diagnosis of the neurological stage of human African trypanosomiasis: update and perspectives], Med Trop [Internet]. 2008; 68(1):17–23. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uid=18478764

38. Courtieux B, Pervieux L, Vatunga G, Marin B, Josenando T, Jauberteau-Marchan MO, et al. Increased CXCL-13 levels in human African trypanosomiasis meningo-encephalitis. Trop Med Int Heal. 2009; 14(5):529–34.

39. Lejon V, Legros D, Rosengren L, Etchegorry M, Büscher P. A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. Am J Trop Med Hyg. 2009; 3(6):1–10.

40. Lejon V, Legros D, Rosengren L, Etchegorry M, Büscher P. Biological data and clinical symptoms as predictors of astrogliosis and neurodegeneration in patients with second-stage Trypanosoma brucei gambiense sleeping sickness. Am J Trop Med Hyg. 2001; 65(6):931–5. PMID: 11792001